NF-κB-IN-8

• UNSPSC Description:

  NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI)[1].

• Target Antigen:

  NF-κB

• Type:

  Reference compound

• Related Pathways:

  NF-κB

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/nf-κb-in-8.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC=CC(COC2=CC=C(C=C2)/C=C/C(NC3=NC4=C(N3)C=CC=C4)=O)=C1

• Molecular Weight:

  399.44

• References & Citations:

  [1]Li X, et al. Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2. Eur J Med Chem. 2023 Apr 5;252:115289.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2924565-59-1